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Carcinogenesis Bioassay Results from
the National Toxicology Program
James Huff*
This article begins a series of condensations on
the National Toxicology Program's (NTP) toxicol-
ogy and carcinogenesis bioassay results as summa-
rized from the NTP Technical Report collection.
This first compilation lists those 40 carcinogenesis
bioassay studies (Table 1) that have undergone
both NTP staff interpretation and evaluation as
well as external peer review and critique. The
majority of these studies were initiated by the
National Cancer Institute's Carcinogenesis Testing
Program, now part of the National Institute of
Environmental Health Sciences, National Toxicol-
ogy Program.
Precis on individual NTP Technical Reports will
be submitted for publication in Environmental
Health Perspectives (EHP) at the same time that
the approved reports are delivered for printing.
For instance, information and data condensations
on four recently printed carcinogenesis bioassay
reports [caprolactam, cytembena, di(2-ethylhexyl)
adipate, and FD&C Yellow No. 6] appear as
separate inserts following this introductory article.
Considerably more abbreviated results are pub-
lished routinely in the NTP Technical Bulletins.
More extensively treated manuscripts are being
prepared for publication consideration in EHP and
in other recognized peer-review journals. This
allows not only more rapid and wider dissemination
ofresults generated by the NTP, but permits open,
interchangebetweenscientists/organizationsengaged
or interested in similar research and testing activi-
ties.
For orientation purposes, the following overview
highlights the National Toxicology Program, the
chemical nomination and selection process, and the
toxicology and carcinogenesis bioassay program.
*National Toxicology Program, P. 0. Box 12233, Research
Tliangle Park, North Carolina 27709
National Toxicology Program
The NTP completed its fourth year of operation
and first year in permanent status in Fiscal Year
(FY) 1982. The NTP was established in November
1978asaDepartment ofHealthandHumanServices
(DHHS) cooperative effort to coordinate and pro-
vide information about potentially toxic chemicals
toregulatory andresearch agenciesandtostrengthen
the science base in toxicology. The need for cre-
ation of such a program evolved from increasing
scientific, regulatory, and congressional concerns
about the human health effects of chemical agents
in the environment.
A major reorganization occurred within NIH in
FY 1981: the transfer of the carcinogenesis bioas-
say program from the National Cancer Institute
(NCI) to the National Institute of Environmental
Health Sciences (NIEHS) was approved by the
Secretary, DHHS, in the fourth quarter of FY
1981. Further, at the beginning of FY 1982, the
Secretarygranted permanent statustothe National
Toxicology Program.
Under the broad objective of providing the
necessary scientific information for prevention of
human disease related to chemical exposure, the
NTP emphasizes four principal goals: (1) broaden
the toxicological characterization of chemicals that
are tested; (2) increase the rate ofchemical testing
(as funding will permit); (3) develop protocols
appropriate for regulatory needs; and (4) communi-
cate program plans and results to governmental
agencies, the medical and scientific communities,
and the public.
Although testing chemicals for toxicity, particu-
larly for carcinogenicity and mutagenicity, remains
an important program focus, increasing emphasis
over the first four years has been placed on
short-term test methods development and valida-
tion. A second primary emphasis continues to beJ. E. HUFF
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the broadening of the testing protocols through
addition of other specific studies to the prechronic
phases (single, 14-day, and 90- or 120-day studies)
ofthe long-term bioassay'and, to a lesser extent, to
the chronic phase (104 weeks) ofthe bioassay.
Accomplishments of NTP programs during FY
1981 and program plans for FY 1982 are described
in the NTP Annual Planfor Fiscal Year 1982.
NTP Chemical Nomination and
Selection
Because more chemicals are nominated for NTP
consideration than can be selected for study, the
NTP Executive Committee formulated a set of
program guidelines. These resultant eight chemical
selection criteria motivate an NTP matrix which
operates throughout the NTP. All research, testing
and test development/validation efforts start here.
The NTP Executive Committee acts under the
principle that industry will test chemicals forhealth
and environmental effects as intended and man-
dated by Congress under legislative authorities.
Therefore, the NTP, using these chemical selection
principles, will test: (1) chemicals found in the
environment that are not closely associated with
commercial activities; (2) desirable substitutes for
existing chemicals, particularly therapeutic agents,
that might not be developed or tested without
federal involvement; (3) chemicals that should be
tested to improve scientific understanding ofstruc-
ture-activity relationships and thereby assist in
defininggroups ofcommercial chemicals thatshould
be tested by industry; (4) certain chemicals tested
by industry, or by others, the additional testing of
which by the federal government is justified to
verify the results; (5) previously tested chemicals
for which other testing is desirable to cross-
compare testing methods; (6) "old chemicals" with
the potential for significant human exposure which
are of social importance but which generate too
little revenue to support an adequate testing pro-
gram (some ofthese may be "grandfathered" under
FDA laws); (7) two or more chemicals together,
when combined human exposure occurs (such test-
ing probably cannot be required of industry if the
products of different companies are involved); and
(8) in special situations, as determined by the
Executive Committee, marketed chemicals which
have potential for large-scale -and/or intense human
exposure, even if it may be possible to require
industry to perform the testing.
Most chemicals are nominated and selected for
testing because toxicologic information is lacking
and because the potential exists for human expo-
sure. Other important criteria include production
193
levels, physical and chemical properties, agency
interests, and significance to society. The NTP
toxicologytesting strategy: identify with assurance
the major toxic effects for each chemical studied.
This includes (in addition to identifying chemical
mutagens and carcinogens) damage to critical tar-
get organs such as the reproductive system, lungs,
liver, and nervous system.
Nominations ofchemicals fortoxicological testing
are submitted by the NTP participatingagencies as
well as othergovernment agencies, industry, labor,
and the public. The nominating source is asked to
submit the name of the chemical, the particular
toxicological tests desired, the rationale fortesting,
and to provide the available background data on
production, use, exposure, environmental occur-
rence, and toxic properties in a supporting sum-
mary document.
An initial examination determines which pro-
posed chemicals have already been tested, are
being tested, are scheduled for test, or have been
previously considered and rejected for testing by
the NTP or its predecessors.
Literature containing relevant data is assessed
and literature summaries are prepared for each
chemical. Included in each literature summary are
sections on chemical identification and physical
properties, surveillance index (production, use,
environmental occurrence, and available regulatory
status and exposure limits), human exposure and
health effects, research hypothesis to be tested,
categories ofstudy, and source ofand reason(s) for
nomination. Chemicals nominated for mutagenicity
testing are reviewed only with regard to the
available genetic toxicology information.
These summaries are reviewed and evaluated by
the Chemical Evaluation Committee (composed of
representatives from CPSC, EPA, FDA, OSHA,
NCI, NCTR, NIEHS, NIOSH, and NTP)* who
recommend the type(s) oftesting to be considered.
All suggestions and recommendations for future
research and testing activities must satisfy at least
one of the eight NTP principles of chemical selec-
tion.
Announcements listing the chemicals and the
recommended types of testing appear in the Fed-
eral Register and the NTP Technical Bulletin.
These notices solicit comments as well as informa-
*CPSC = Consumer Product Safety Commission; EPA =
EnvironmentalProtectionAgency;OSHA = Occupational Safety
& Health Administration; NCI = National Cancer Institute;
NCTR = National CenterforToxicologicalResearch; NIEHS =
National Institute ofEnvironmental Health Sciences; NIOSH =
National Institute for Occupational Safety and Health; and NTP
= National Toxicology Program.194
tion on completed, ongoing, and planned testing in
the private sector. These steps are taken to encour-
age others outside the immediate program to par-
ticipate in the NTP evaluation and selection pro-
cess, as well as to specifically prevent unnecessary
duplication. Revised summaries with additional
public input are forwarded tothe Board ofScientific
Counselors for review. The Board evaluates these
data and makes recommendations to the Executive
Committee.
Final summaries are submitted to the NTP
Executive Committeewhodecidewhethertoselect,
defer, orreject the chemicals fortesting. Following
Executive Committee action, the chemicals are
referred by the NTP Steering Committee to one or
moreparticipatingagencieswithintheNTP: NIEHS,
NIOSH, NCTR. At this stage certain approved
chemicals may be identified as being inappropriate
candidates for testing as a result of technical or
budgetary reasons or in some cases public informa-
tion describing ongoing testing may only have been
submitted following Executive Committee decision.
Such chemicals are then returned to the Executive
Committee for reconsideration.
All chemicals selected are thentested as time and
resources permit.
Toxicology and Carcinogenesis
Bioassay
The "standard" two-year carcinogenesis bioassay
remains as the most definitive method fordetecting
chemical carcinogens in animals. The standard
protocol as developed by the NCI (and frequently
still used by the NTP) typically uses two rodent
species (usually Fischer344 rats and B6C3F1 mice),
both sexes, and administration of multiple dose
levels (concurrent controls, low dose, and high
dose) of a chemical to groups of 50 animals, begin-
ning at weaning and ending after two years. These
experiments are designed primarily to determine
whether selected chemicals produce cancer in ani-
mals. Chemicals tested in the NTP Carcinogenesis
Bioassay Program are chosen primarily on the
bases of human exposure, available (or lack of)
toxicology data, level of production, and chemical
structure. Selection per se is not an indicator of a
chemical's carcinogenic potential.
Negative results, inwhichthe test animals do not
have a greater incidence of cancer than control
animals, do not necessarily mean that a test chemi-
cal is not a carcinogen, inasmuch as the experi-
ments are conducted under a limited set of condi-
tions. Positive results demonstrate that a test
chemical is carcinogenic for animals under the
J. E. HUFF
conditions ofthe test and indicate that exposure to
the chemical is a potential hazard to humans. The
determination ofthe risk to humans from chemicals
found to be carcinogenic in animals often requires a
wideranalysis which at present extends beyond the
purview of these studies.
The results of the bioassay also serve as the
reference base for the validation of short-term
carcinogenesis assays. Two additional objectives
have been identified as priority items: (1) to expand
the bioassay experimental protocols to extend and
better characterize the toxicologic proffle ofchemi-
cals; and (2) to investigate, develop, and validate
accurate, less costly, and more rapid methods for
detecting carcinogenic potential.
Under the NTP, the carcinogenesis bioassay
procedure(s) has been and continues to be changed
to meet the objective of a broadened toxicologic
characterization of chemicals and, further, to lead
or stay abreast of advancing scientific develop-
ments. Prior to NTP involvement, the prechronic
phases of the bioassay-which include single dose
(acute), 14-day repeated dose, and 90- to 120-day
repeated dose studies-were conducted to deter-
mine gross toxicity and general target organ effects
at different dose levels as a primary basis for
setting appropriate doses forthe two-year bioassay
studies. Now, the NTP has begun to gather rou-
tinely other information related to target organ
effect: chemical disposition, fertility and reproduc-
tion, urinalysis, and hematology also are obtained
from the prechronic studies-especially the 90-day
study; certain other specific studies as applicable
are included in the chronic two-year studies as well.
Once those parameters thatmaybe altered through
exposure to the tested chemicals are identified,
then suspect chemicals are referred to specific
organ system groups for more detailed study ofthe
functional, biochemical, and morphologic effects of
the test compounds. Also, wider analysis of the
quantitative and comparative absorption, distribu-
tion, metabolism, and excretion patterns may be
desired. For instance, 28 (70%) of the 40 chemical
starts in FY 1980 included specific toxicology stud-
ies in the prechronic testing phase. All chemicals
started on test in FY 1981 had an expanded design
includingotherselect studies. Significantly all chem-
icals selected for chronic bioassay will be profiled
for chemical disposition patterns. The goal is to
ensure that all major toxic effects will be identified
for each chemical being considered for long-term
bioassays.
With this composite information base, the doses
for the chronic study are selected. The high dose,
termed the estimated maximum tolerated dose
(EMTD), represents the highest dose ofa chemicalCARCINOGENESIS BIOASSAY RESULTS FROM THE NTP
or substance given during a chronic study that can
be predicted not to alter the treated animals'
normal longevity from toxic effects other than
carcinogenicity. The low dose ordinarily equals 1/2
EMTD. Other empirical factors include weight
gain/foodconsumption data; forinstance, adecrease
in weight gain near 10-15% (not associated with a
tumorigenic response) is often used as a general
indication that the EMTD was achieved.
Prior to commencing the actual long-term carci-
nogenesis bioassay, all chemicals undergo genetic
toxicology testing in at least five in vitro short-term
assays: (1) gene mutations in backteria-Salmon-
ella typhimurium microsome; (2) gene mutations
in mammalian cells-mouse lymphoma (L5178Y,
thymidine kinase); (3) chromosome damage in mam-
malian cells-cytogenetic damage and sister chro-
matid exchange (in vitro, CHO); (4) a mammalian
cell transformation assay-(BALB/c -3T3); and (5)
a direct measure of DNA damage/repair (which
does not necessarily result in mutation or transfor-
mation)-unscheduled DNA synthesis (rat hepato-
cytes). These data, together with other prechronic
bioassay information, are used by the experimental
design groups for preparing appropriate study
protocols and are used by staff for assisting in
establishingpriorities for chemicals queued intothe
long-term carcinogenesis bioassay. A key decision
that must be made at this juncture between the
completion of the prechronic phase and the begin-
ning of the chronic study centers directly on
whether indeed the lifetime bioassy should be
done at all.
Thus, while the lifetime animal bioassay remains
the best procedure for determining the carcino-
genic potential ofchemicals, NTP does not ordinar-
ily use a standardized design. Rather the design is
adapted to the special testing needs identified for
the particular chemical. The NTP tailors its testing
protocols to the particular chemicals based on the
results from the prechronic testing phases, on
available literature, and on structure-activity rela-
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tions. These new protocols permit better, more
specific information to be generated for the tested
compounds, which increases the effectiveness of
the tests forpotential human risk estimations. Such
protocols also will be useful as guidelines for testing
undertaken by other agencies and by industry. As
examples, the NTP continues to pursue actively
other design methodologies-increase the number
ofdose levels, "unbalanced" distribution ofanimals
among dose groups, interim kills, and reduced
essential histopathology.
Bioassay Results
During FY 1981, 23 long-term carcinogenesis
bioassays were completed and the conclusions and
data were evaluated and approved by the NTP staff
review committee and subsequently by the exter-
nal NTP peerreview panel. Under the conditions of
these carcinogenesis bioassays, 12 (52%) were con-
sidered negative, 10 (44%) positive, and 1 (4%)
equivocal. One, polybrominated biphenyl (PBB)
mixture (Firemaster FF-1), was conducted using a
broadened experimental protocol aimed at provid-
ing a better dose-response determination (through
use of six doses) and at giving more data on
toxicologic end points other than induction of can-
cer. Nontumor toxicities of this PBB included
porphyrogenic effects, decreases in serum thyroid
hormones, hematotoxicity, enzyme alterations, and
hepatotoxicity.
Since the NTP became actively involved in the
carcinogenesis bioassay technical report review
process, 40 experimental studies have been com-
pleted (with draft or final reports being issued): 20
(50%) positive, 14 (35%) negative, 4 (10%) equivo-
cal, 2 (5%) inadequate; see Table 1.
As of February 1982: (1) Twenty-five chemicals
have been newly assigned to the testing labora-
tories (Table 2). (2) Seventy-nine chemicals (89
separate studies) were in the prechronic testing
Table 2. Chemicals assigned to testing laboratories (February 1982).
Azodicarbonamide (inhalation) Glutaraldehyde Propantheline bromide
o-Benzyl-p-chlorophenol N-Isopropyl-N'-phenyl-p-phenylenediamine Quercetin
C.I. Acid Red 114 Isoproterenol hydrochloride Riddelliine
C.I. Direct Blue 15 Manganese sulfate Triamterene
C.I. Direct Blue 218 Methdilazine (gavage) 1,2,3-Trichloropropane
3,3'-Dimethoxybenzidine Methdilazine (feed) Tricresyl phosphate
3,3'-Dimethylbenzidine Methylphenidate Trimellitic anhydride
N,N-Dimethylformamide p-Nitroaniline Turmeric, oleoresin (curcumin)
Ethyl benzene o-Nitroanisole196
phase (Table 3); mostinclude one ormore additional
toxicology studies in the prechronic testing phase.
(3)Ninety-sixchemicalsfrequentthechronictwo-year
testing stage (Table 4). There are a number ofnew
or ongoing long-term carcinogenesis studies con-
cerned with chemicals or mixtures of chemicals
which humans encounter in occupational settings
(benzene, diesel fuel marine, gentian violet, napth-
thalene, Navy fuels JP-5, as examples). (4) Twenty-
nine chemicals (35 separate studies) are in the
histopathology phase (Table 5). (5) For 10 chemi-
cals, reports are being written or draft reports are
J. E. HUFF
in program review (Table 6). Including the new
chemical starts, there were 185 bioassays in either
the prechronic or the chronic bioassay testing
phases at the end ofFY 1981 (Tables3 and4). (6) In
FY 1982, the NTP expects to complete (through
peer review) 29 long-term bioassays (Tables 6 and
7).
Abstracted from the peer-reviewed approved
draft technical reports, Table 1 contains assorted
information about the particular chemical carcino-
genesis study (CAS Registry Number, peerreview
date, use, route and dose, contract laboratory, and
Table 3. Chemicals in the prechronic testing phase (February 1982).
Acetonitrile
Allyl glycidyl ether
1-Amino-2,4-dibromoanthraquinone
Amphetamine sulfate
Azodicarbonamide (gavage)
Benzaldehyde
2,2-Bis(bromomethyl)-1,3-propanediol (gavage)
2,2-Bis(bromomethyl)-1,3-propanediol (dermal)
-y-Gamma-butyrolactone
3-Cadinene
Caffeine
Carbon disulfide
d-Carvone
Catechol
Chloramine
Chloramphenicol
Chloroacetophenone
p-Chloroaniline
o-Chlorobenzalmalononitrile
Chlorpromazine hydrochloride
1,8-Cineol (eucalyptol)
Cinnamaldehyde
C.I. Pigment Red 23
C.I. Pigment Red 3
Coumarin
2,4-Diaminophenol hydrochoride
4,4'-Diamino-2,2'-stilbenedisulfonic acid
2,3-Dibromo-l-propanol (gavage)
2,3-Dibromo-1-propanol (dermal)
Diethyl phthalate
3,4-Dihydrocoumarin
Dimethoxane
Dimethyloldihydroxyethyleneurea (gavage)
Dimethyloldihydroxyethyleneurea (inhalation)
Doxylamine
Epinephrine hydrochloride
1,2-Epoxybutane
Ethyl bromide
Ethyl chloride
Ethylenediamine
Ethylene glycol
Ethylenethiourea
Formaldehyde
Furan
Furfural
Furfuryl alcohol
HC Yellow 4
Hexachlorocyclopentadiene
Hexachloroethane
Hydroquinone
4-Hydroxyacetanilide
5-Hydroxytryptophan
Isobutyl nitrite
Mercuric chloride
Methapyriline (acidified H20)
Methapyriline (neutral H20)
6-Methylcoumarin
N-Methylolacrylamide
Monochloroacetic acid
Nitrobenzene (gavage)
Nitrobenzene (dermal)
Ochratoxin A
Palladium (II) chloride
Pentachloroanisole
Pentachlorophenol, Dowicide EC-7
Pentachlorophenol, DP-2
Pentachlorophenol, purified
Pentachlorophenol, technical
Phenolphthalein
Phenytoin
Polybrominated biphenyl (FF-1)
Polysorbate 80
Probenecid
Promethazine
Pyrilamine
p-Quinone
Resorcinol
Sodium azide
Tetrahydrofuran
Tetranitromethane
Thenyldiamine
Titanocene dichloride
Toluene, commercial (gavage)
Toluene, commercial (inhalation)
Tripelenamine
Tris(2-chloroethyl) phosphate
1-Vinyl-3-cyclohexene dioxide (gavage)
1-Vinyl-3-cyclohexene dioxide (dermal)
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Table 4. Chemicals in the chronic testing phase (February 1982).
2-Amino-4-nitrophenol
2-Amino-5-nitrophenol
Ampicillin trihydrate
Benzene
Benzofuran
Benzyl alcohol
Benzyl chloride
Boric acid
Bromodichloromethane
Bromoform
1,3-Butadiene
2-Butanone peroxide
t-Butyl alcohol
n-Butyl chloride
Castor oil
Chlorendic acid
Chlorinated trisodium phosphate
Chlorodibromomethane
3-Chloro-2-methylpropene
Chlorowax 40
Chlorowax 500C
Chlorpheniramine maleate
C.I. Acid Orange 3
C.I. Basic Red 9 (p-rosaniline)
C.I. Disperse Blue 1
Coconut oil acid diethanolamine
Decabromodiphenyl oxide
p-Dichlorobenzene
2,4-Dichlorophenol
Dichlorvos
Diesel fuel marine
Diethanolamine
Diglycidylresorcinol ether (DGRE)
N,N-Dimethylaniline
Dimethyl hydrogenphosphite
Dimethyl methylphosphonate
Dimethyl morpholinophosphoramidate
Dimethylvinylchloride
Diphenhydramine hydrochloride
Ephedrine sulfate
1,2-Epoxyhexadecane
Erythromycin stearate
Ethylene chlorohydrin
Ethylene glycol monoethyl ether
Ethylene oxide
Furosemide
Gentian violet
Glutaraldehyde
Glycidol
HC Blue 2
HC Red 3
Hexylresorcinol
Hydrochlorothiazide
lodinated glycerol
Isophorone
Lauric acid diethanolamine
D-Limonene
Malonaldehyde
2-Mercaptobenzothiazole
8-Methoxypsoralen
al-Methylbenzyl alcohol
Methyl carbamate
Methyl Dopa
Methylene chloride
Methyl methacrylate
Nalidixic acid
Navy fuels JP-5 (petroleum derived)
Nitrofurantoin
Nitrofurazone
Oleic acid diethanolamine
Oxytetracycline hydrochloride
Penicillin V potassium
Pentachloronitrobenzene
Pentaerythritol tetranitrate
Phenylbutazone
Phenylephrine hydrochloride
N-Phenyl-2-naphthylamine
o-Phenylphenol
Pyridine
Rhodamine 6G
Rotenone
Roxarsone
Sodium fluoride
Styrene oxide
Succinic anhydride
Sulfamethazine
Tetrachloroethylene
Tetracycline hydrochloride
Tetrakis(hydromethyl)phosphonium chloride (THPC)
Tetrakis(hydroxymethyl)phosphonium sulfate (THPS)
Trichlorfon
Tris(2-ethylhexyl) phosphate
4-Vinylcyclohexene
Vinyl toluene
Witch hazel
Xylenes
Xylene sulfonic acid, sodium salt
the NTP scientist responsible for design, imple-
mentation, interpretation, and report preparation)
and the abbreviated results. This table includes
summary information on the six chemical carcino-
genesis bioassays evaluated in December 1981, on
the 23 reported in FY 1981, on the nine completed
and peer reviewed in June 1980, and on two
considered inadequate (TCDD-DMBA dermal and
asbestos-DMH oral studies). The letter "P" follow-
ing the Technical Report (TR) number in column
two means that the NTP Technical Report has
been published; detailed condensations offour carci-
nogenesis bioassays so designated follow this arti-
cle. The others settle into various stages ofpublica-
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Table 5. Chemicals in the histopathology phase (February 1982).
Asbestos, amosite Diglycidylresorcinol ether (DGRE) Monuron
Asbestos, chrysotile (SR) Dimethylbenzanthracene (DMBA)/ p-Nitrophenol
Asbestos, chrysotile (IR) tetradecanoyl phorbol acetate (TPA) Propylene
Asbestos, crocidolite Dodecyl alcohol, ethoxylated Propylene oxide
Chlorobenzene Ethyl acrylate Sodium dodecyl sulfate
C.I. Acid Yellow 73 Gilsonite Sodium (2-ethylhexyl) alcohol sulfate
Diallyl phthalate (rats) HC Blue 1 Tetrachloroethylene
o-Dichlorobenzene 8-Hydroxyquinoline Tremolite
1,2-Dichloropropane Methylene chloride 1,1,1-Trichloroethane
1,3-Dichloropropane Mirex Trichloroethylene
Table 6. Chemicals in the draft report-program review process (February 1982).
Allyl isovalerate Geranyl acetate 2,4-Toluene diisocyanate and
Ascorbic acid Melamine 2,5-toluene diisocyanate
Benzyl acetate 4,4'-Methylenedianiline dihydrochloride Trichloroethylene
Diallyl phthalate (mice) Tetracholoroethylene
Table 7. Chemicals for which carcinogenesis bioassays will be completed (through peer review) in FY 1982 (February 1982).a
Agaritineb Dimethylbenzanthracene (DMBA)/ Tetrachloroethylene
Asbestos, amosite 12-O-tetradecanoylphorbol-13-acetate (TPA) Tremolite
Asbestos, chrysotile (short range) D-Mannitol Trichloroethylene
Asbestos, chrysotile (intermediate range) N-Nitrosodiethanolamineb 2,6-Xylidine
Asbestos, crocidolite Propyl gallate Zearalenone
Bis(2-chloro-1-methylethyl) ether (BCMEE) Rotenone Ziram
and 2-chloro-1-methylethyl Sodium (2-ethylhexyl) alcohol sulfate
(2-chloropropyl) ether 1,1,1,2-Tetrachloroethane
aPlus those ten chemicals listed in Table 6.
bJournal publication (no technical report).
tion; these will be featured in future carcinogenesis
bioassay results articles from the National Toxicol-
ogy Program.
DocumentAvailability-To receive copies oftheNTPAnnual
PlanforFiscal Year1982 (and for FY 1981), theNTP Technical
Bulletin, and the NTP Technical Reports on a particular
chemical carcinogenesis bioassay study, write: Mr. S. d'Arazien,
NTP Public Information Office, National Toxicology Program,
P. 0. Box 12233, Research Triangle Park, North Carolina27709
(919-541-3991; FTS 8-629-3991).
Technical Information-For more detailed information about
completed, ongoing, or planned carcinogenesis bioassay studies,
contact: Ms. Joan Chase, National Toxicology Program, 3A06
Landow Building, 7910WoodmontAvenue, Bethesda, Maryland
20205 (301-496-1152; FTS 8-496-1152).
Chemical Nominations -Persons ororganizations wishing to
nominate otherchemicals fortestingshould send the name ofthe
chemical, testing requested, rationale, and other supporting
information to: Dr. D. Canter, Chemical Nominations, National
Toxicology Program, Building 31, Room 2B55, Bethesda, Mary-
land 20205.
I thank Dr. Larry Hart for use ofthe preprint version ofthe
NTP Annual Planfor Fiscal Year 1982; Dr. Joseph Haseman
forhelpingprepare and verify Table 1; Mr. Jeffrey Sensenig and
Mr. R. Michael Rowley for developing the BIOTEXT software
ifie (Table 1); Ms. Florence Jordan and Ms. Pamela Lemon for
initiating and maintaining the BIOTEXT file; each listed Chemi-
cal Manager; and Ms. Gerry Wandrisco for assistance in prepar-
ing this manuscript.
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